NCT00988403

Brief Summary

Fructan is a carbohydrate polymer that is composed of fructose and a terminal glucose moiety . Fructans are naturally found in artichokes (6.1 grams/serving), leeks (5.9 grams/serving), onion bulbs (1.01 grams/serving), flour (4.0 grams/serving), garlic (.52 grams/serving), watermelon (.92 grams/serving), nectarines (.27 grams/serving) and white peaches (.50 grams/serving). Because fructans are present in many common foods, people typically ingest high levels of fructan. The most common structural forms of fructan are inulin, levanare and geraminan . The human body absorbs only 5% of fructan, however it is estimated that the daily intake in the USA may vary between 1-20 grams, and possibly higher due to the recently discovered benefits of inulins . Dietary trends indicate that high levels of fructans are common in the European and American diet, as more wheat based products such as breakfast cereal, pasta, and bread are consumed. Fructans may not be well tolerated by some subjects and its malabsorption may result in gastrointestinal (GI) symptoms such as heartburn, belching, abdominal pain, diarrhea, gas, and bloating; and this is especially true when higher doses are ingested. Unlike glucose, fructans are not efficiently digested or absorbed by the small intestine. The mechanism for malabsorption is related to the inability to hydrolyze glycosidic linkages in the complex polysaccharide, resulting in the delivery of malabsorbed fructans to the large bowel1. In the colon, the malabsorbed fructans are rapidly fermented, and byproducts of this fermentation include H2, CH4, and other gases that may contribute to bowel symptoms. Furthermore, the small molecular nature of fructans results in an osmotic effect which draws more water into the small intestine and causes bloating and diarrhea. Ingestion of high doses of fructans can cause symptoms in healthy adults, but may cause more bothersome symptoms in subjects with Irritable Bowel Syndrome (IBS). Earlier studies have identified that IBS affects between 10 and 15% of the population in the United States. Ingestion of 10-20 grams of fructan daily may cause symptoms of IBS, and restricting fructan intake in a diet may reduce symptoms in a variety of gastrointestinal disorders. One study recently published found that dietary restriction of fructan and fructose was responsible for symptomatic improvement in patients with IBS. Hypothesis: The investigators hypothesize that healthy individuals will absorb fructan 7.5 gram and 10 gram doses, and will experience malabsorption at the 12.5 gram fructan dose.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for not_applicable healthy-volunteers

Timeline
Completed

Started Jun 2009

Longer than P75 for not_applicable healthy-volunteers

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2009

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 22, 2009

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 2, 2009

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2011

Completed
6.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 20, 2018

Completed
Last Updated

July 23, 2018

Status Verified

July 1, 2018

Enrollment Period

2.2 years

First QC Date

September 22, 2009

Last Update Submit

July 20, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Hydrogen and Methane Concentration levels

    Measure breath sample concentration for hydrogen and methane levels in parts per million

    3 visits over a 1 month period

Secondary Outcomes (1)

  • Production of GI Symptoms

    3 visits over a 1 month period

Study Arms (4)

Fructan - 7.5

EXPERIMENTAL

Subjects will consume 7.5 grams of fructan

Dietary Supplement: Fructan - 7.5

Fructan - 10 grams

EXPERIMENTAL

Subjects will consume 10 grams of fructan

Dietary Supplement: Fructan - 10

Fructan - 12.5 grams

EXPERIMENTAL

Subjects will consume 12.5 grams of fructan

Dietary Supplement: Fructan - 12.5

5 grams Fructan

EXPERIMENTAL

Experimental - 5 grams Fructan Subjects will consume 5 grams of Fructan.

Dietary Supplement: Fructan -- 5 grams

Interventions

Fructan - 7.5DIETARY_SUPPLEMENT

Subjects will consume 7.5 grams of fructan

Also known as: 7.5 grams of Inulin
Fructan - 7.5
Fructan - 10DIETARY_SUPPLEMENT

Subjects will consume 10 grams of fructan

Also known as: 10 grams of Inulin
Fructan - 10 grams
Fructan - 12.5DIETARY_SUPPLEMENT

Subjects will consume 12.5 grams of fructan

Also known as: 12.5 grams of Inulin
Fructan - 12.5 grams
Fructan -- 5 gramsDIETARY_SUPPLEMENT

Subjects will consume 5 grams fructan.

Also known as: 5 grams of Inulin
5 grams Fructan

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy volunteers between the ages of 18-70 years, with no previous history of gastrointestinal problems or any other ailments, no history of gastrointestinal surgery except appendectomy, cholecystectomy, caesarean section, hysterectomy and currently not using any medication except contraceptive pill, multivitamin, or aspirin.
  • They will be asked to fill out a Review of Systems health history (Appendix 2) and the Mayo Clinic Bowel Disease Questionnaire (Appendix 3) and will undergo a routine physical examination. Only patients who are asymptomatic and deemed healthy from the aforementioned screening procedure will be eligible.

You may not qualify if:

  • Currently taking medication for any ailment including OTC medication (excluding aspirin, multivitamins, and oral contraceptives)
  • History of gastrointestinal problems including bloating, gas, food intolerances or reflux symptoms
  • Any major abdominal surgery (except appendectomy, cholecystectomy, caesarean section, hysterectomy) or coexisting medical problem
  • Known food allergies
  • Prisoners
  • Cognitive Impairment or any other inability to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States

Location

Study Officials

  • Satish Rao, MD, PhD

    Augusta University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 22, 2009

First Posted

October 2, 2009

Study Start

June 1, 2009

Primary Completion

August 31, 2011

Study Completion

July 20, 2018

Last Updated

July 23, 2018

Record last verified: 2018-07

Locations